Development of in vitro methods to predict induction of CYP1A2 and CYP3A4 in humans

Assay and Drug Development Technologies

Volumn 5, Issue 6, 2007, Pages 793-804

  Grover, G Scott ^a   Brayman, Timothy G ^a   Voorman, Richard L ^a   Ware, Joseph A ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; PREGNANE X RECEPTOR;

ARTICLE; CELL IMMORTALIZATION; CELL VIABILITY; CONTROLLED STUDY; CRYOPRESERVATION; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CULTURE;

CELL SEPARATION; CELL SURVIVAL; CELLS, CULTURED; CRYOPRESERVATION; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; GENES, REPORTER; HEPATOCYTES; HUMANS; RECEPTORS, ARYL HYDROCARBON; RECEPTORS, STEROID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA;

EID: 38049093921     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2007.087     Document Type: Article

References (31)

1. Frye RF: Probing the world of cytochrome p450 enzymes. Mol Interv 2004;4:157-162.
2. Ingelman-Sundberg M: Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 2004;369:89-104.
3. Frotschl R, Chichmanov L, Kleeberg U, Hildebrandt AG, Roots I, Brockmoller J: Prediction of aryl hydrocarbon receptor-mediated enzyme induction of drugs and chemicals by mRNA quantification. Chem Res Toxicol 1998;11:1447-1452.
4. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT: Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003;42:819-850.
5. Zilly W, Breimer DD, Richter E: Pharmacokinetic interactions with rifampicin. Clin Pharmacokinet 1977;2:61-70.
6. Zevin S, Benowitz NL: Drug interactions with tobacco smoking. An update. Clin Pharmacokinet 1999;36:425-438.
7. Tirona RG, Kim RB: Nuclear receptors and drug disposition gene regulation. J Pharm Sci 2005;94:1169-1186.
8. Burbach KM, Poland A, Bradfield CA: Cloning of the Ah-receptor cDNA reveals a distinctive ligand-activated transcription factor. Proc Natl Acad Sci U S A 1992;89:8185-8189.
9. Poland A, Glover E: 2,3,7,8-Tetrachlorodibenzo-p-dioxin: a potent inducer of -aminolevulinic acid synthetase. Science 1973;179:476-477.
10. Poland A, Glover E, Kende AS: Stereospecific, high affinity binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin by hepatic cytosol. Evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase. J Biol Chem 1976;251:4936-4946.
11. Gasiewicz TA, Kende AS, Rucci G, Whitney B, Willey JJ: Analysis of structural requirements for Ah receptor antagonist activity: ellipticines, flavones, and related compounds. Biochem Pharmacol 1996;52:1787-17803.
12. Kafafi SA, Afeefy HY, Ali AH, Said HK, Abd-Elazem IS, Kafafi AG: Affinities for the aryl hydrocarbon receptor, potencies as aryl hydrocarbon hydroxylase inducers and relative toxicities of polychlorinated biphenyls. A congener specific approach. Carcinogenesis 1993;14:2063-2071.
13. Poland A, Knutson J, Glover E: Studies on the mechanism of action of halogenated aromatic hydrocarbons. Clin Physiol Biochem 1985;3:147-154.
14. Hoffman EC, Reyes H, Chu FF, Sander F, Conley LH, Brooks BA, et al.: Cloning of a factor required for activity of the Ah (dioxin) receptor. Science 1991;252:954-958.
15. Postlind H, Vu TP, Tukey RH, Quattrochi LC: Response of human CYP1-luciferase plasmids to 2,3,7,8-tetrachlorodibenzo-p-dioxin and polycyclic aromatic hydrocarbons. Toxicol Appl Pharmacol 1993;118:255-262.
16. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, et al.: An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 1998;92:73-82.
17. Ogg MS, Williams JM, Tarbit M, Goldfarb PS, Gray TJ, Gibson GG: A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro. Xenobiotica 1999;29:269-279.
18. Pascussi JM, Drocourt L, Fabre JM, Maurel P, Vilarem MJ: Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol Pharmacol 2000;58:361-372.
19. Wang H, Faucette SR, Gilbert D, Jolley SL, Sueyoshi T, Negishi M, et al.: Glucocorticoid receptor enhancement of pregnane X receptor-mediated CYP2B6 regulation in primary human hepatocytes. Drug Metab Dispos 2003;31:620-630.
20. Chen Y, Ferguson SS, Negishi M, Goldstein JA: Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J Pharmacol Exp Ther 2004;308:495-501.
21. Goodwin B, Hodgson E, Liddle C: The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 1999;56:1329-1339.
22. Jackson JP, Ferguson SS, Moore R, Negishi M, Goldstein JA: The constitutive active/androstane receptor regulates phenytoin induction of Cyp2c29. Mol Pharmacol 2004;65:1397-1404.
23. Wang H, Faucette S, Moore R, Sueyoshi T, Negishi M, LeCluyse E: Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J Biol Chem 2004;279:29295-29301.
24. Ramachandran V, Kostrubsky VE, Komoroski BJ, Zhang S, Dorko K, Esplen JE, et al.: Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes. Drug Metab Dispos 1999;27:1194-1199.
25. Sonderfan AJ, Arlotto MP, Dutton DR, McMillen SK, Parkinson A: Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Arch Biochem Biophys 1987;255:27-41.
26. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, et al.: Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 1993;265:401-407.
27. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J: Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 1982;42:3858-3863.
28. Schuetz EG, Li D, Omiecinski CJ, Muller-Eberhard U, Kleinman HK, Elswick B, et al.: Regulation of gene expression in adult rat hepatocytes cultured on a basement membrane matrix. J Cell Physiol 1988;134:309-323.
29. Silva JM, Morin PE, Day SH, Kennedy BP, Payette P, Rushmore T, et al.: Refinement of an in vitro cell model for cytochrome P450 induction. Drug Metab Dispos 1998;26:490-496.
30. Bagrintseva K, Schwab R, Kohl TM, Schnittger S, Eichenlaub S, Ellwart JW, et al.: Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells. Blood 2004;103:2266-2275.
31. Raucy JL: Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos 2003;31:533-539.